Management of cellulitis in a pediatric emergency department

Pediatric Emergency Care

Volumn 23, Issue 11, 2007, Pages 805-811

  Khangura, Simi ^a   Wallace, Jonathan ^a   Kissoon, Niranjan ^a   Kodeeswaran, Tanuja ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Antibiotics; Cefazolin; Cellulitis; Probenecid; Treatment

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFALEXIN; CEFAZOLIN; CEFAZOLIN PLUS PROBENECID; CEFTRIAXONE; CEFUROXIME; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; ARTICLE; CELLULITIS; EMERGENCY WARD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTPATIENT CARE; PEDIATRIC WARD; SCHOOL CHILD; TREATMENT FAILURE;

EID: 36348971670     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/PEC.0b013e31815a032f     Document Type: Article

References (15)

1. Fleisher G, Ludwig S. Cellulitis: a prospective study. Ann Emerg Med. 1980;9(5):246-249.
2. Fleisher G, Ludwig S, Campos J. Cellulitis: bacterial etiology, clinical features, and laboratory findings. J Pediatr. 1980;97(4):591-593.
3. Brown G, Chamberlain R, Goulding J, et al. Ceftriaxone versus cefazolin with probenecid for severe skin and soft tissue infections. J Emerg Med. 1996;14:547-551.
4. Cox VC, Zed PJ. Once-daily cefazolin and probenecid for skin and soft tissue infections. Ann Pharmacother. 2004;38:458-463.
5. Grayson ML, McDonald MM, Gibson K, et al. Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. Clin Infect Dis. 2002;34:1440-1448.
6. Spina SP, Dillon EC. Effect of chronic probenecid therapy on cefazolin serum concentrations. Ann Pharmacother. 2003;37:621-624.
7. Dong SL, Kelly KD, Oland RC, et al. ED management of cellulitis: a review of five urban centers. Am J Emerg Med. 2001;19:535-540.
8. Bradsher RW, Snow RM. Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen. Am J Med. 1984;77:63-67.
9. Gordin FM, Wofsy CB, Mills J. Once-daily ceftriaxone for skin and soft tissue infections. Antimicrob Agents Chemother. 1985;27:648-649.
10. Brown G. Cephalosporin-probenecid drug interactions. Clin Pharmacokinet. 1993;24(4):289-300.
11. Murray H, Stiell I, Wells G. Treatment failure in emergency department patients with cellulitis. CJEM. 2005;7(4):228-234.
12. Sadow KB, Chamberlain JM. Blood cultures in the evaluation of children with cellulitis. Pediatrics. 1998;101:E4.
13. Simor AE, Ofner-Agostini M, Patin S. Surveillance for methicillin-resistant Staphylococcus aureus in Canadian hospitals - a report update from the Canadian Nosocomial Infection Surveillance Program. Can Commun Dis Rep. 2005;31:33-40.
14. Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis. 2005;40:1785-1791.
15. Barton M, Hawkes M, Moore D, et al. Guidelines for the prevention and management of community-associated methicillin-resistant Staphylococcus aureus: a perspective for Canadian health care practitioners. Can J Infect Dis Med Microbiol. 2006;17(suppl):4C-24C.